Infectious Disease
RSSArticles
-
Syphilis RPR May Fluctuate Before Treatment
The more time between testing and treatment, the more likely the change in the titer. Since patients often are called back for treatment, these data suggest clinicians should obtain a repeat rapid plasma reagin at the time these patients return for treatment, effectively establishing a new baseline.
-
What Is the Optimal Duration of Antibiotics for a Complicated UTI with Bacteremia?
An observational study of adults hospitalized with a complicated urinary tract infection and bacteremia revealed seven days of therapy was enough for most cases when they received antibiotics with comparable intravenous and oral bioavailability.
-
APIC 2023: No Hospital Is an Island
‘Isolated rural areas don’t have equal access to healthcare’
-
APIC 2023 Keynote: IPs Must Reclaim Their Power
The 2023 APIC keynote speaker called for infection preventionists to reclaim their narrative, to tell people what they do in no uncertain terms, and to empower others to do likewise.
-
What Is the Optimal Duration of Antibiotics for a Complicated UTI with Bacteremia?
An observational study of adults hospitalized with a complicated urinary tract infection and bacteremia found seven days of therapy was enough for the majority of cases when they received antibiotics with comparable intravenous and oral bioavailability.
-
Idiopathic CD4 Lymphocytopenia
A study of 91 adults with idiopathic CD4 lymphocytopenia demonstrated increased risk of cancers and autoimmune disorders, as well as opportunistic infections.
-
Bird Flu: Is It Becoming a Threat to Humans?
A strain of influenza A virus that is highly pathogenic for birds is capable of infecting humans for whom it poses a potential risk as it continues to evolve and spread.
-
Vaccination Against Mpox Is Effective
Two-dose vaccination with Jynneos is effective in the prevention of mpox (monkeypox), but a better vaccine is desirable, particularly for use in immunocompromised individuals.
-
Induction Therapy for HIV/AIDS-Related Disseminated Histoplasmosis with Single High-Dose Liposomal Amphotericin B
In a Phase II randomized clinical trial involving 118 participants in Brazil with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related disseminated histoplasmosis, induction therapy with single high-dose (10 mg/kg) liposomal amphotericin B was safe and non-inferior as compared with standard dose (3 mg/kg) liposomal amphotericin B given once daily for 14 days.
-
Infectious Disease Alert Updates
Head and Neck Cancer Worse in HIV; Syphilis RPR May Fluctuate Before Treatment